link.springer.com

Arsenic-Based Drugs: From Fowler’s Solution to Modern Anticancer Chemotherapy

  • ️Fri Jan 01 2010

  • Ralph SJ (2008) Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs 2008:260146

    Article  Google Scholar 

  • Li S, Luo X (2003) Compendium of materia medica. Foreign Languages Press, Beijing

    Google Scholar 

  • Jackson R, Grainge JW (1975) Arsenic and cancer. Can Med Assoc J 113:396–401

    CAS  Google Scholar 

  • Evens AM, Tallman MS, Gartenhaus RB (2004) The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28:891–900

    Article  CAS  Google Scholar 

  • Lipscomb JD (1877) Improvement in remedy for fevers. US Patent 186,141

    Google Scholar 

  • Ramsaur MH (1869) Improved medical compound. US Patent 92,209

    Google Scholar 

  • Lentilius R (1684) Ephémérides des curieux de la nature. Dec. 11, an 3 - Obs. 46

    Google Scholar 

  • Friceius M (1710) Cap 2. Tractus de Virtute Venenorum Medica

    Google Scholar 

  • Frank J (1835) Encyclopédie des Sciences Médicales ou traité général méthodique et complet des diverses branches de l'art de guérir. Deuxième division, Médecine : pathologie médicale. Bureau de l'Encyclopédie, Paris

    Google Scholar 

  • Fowler T (1786) Medical reports on the effects of arsenic in the cure of agues, remittent fevers and perodic headaches

    Google Scholar 

  • Hunt T (1848) Minimum fatal dose of arsenic. Prov Med Surg J 12:445

    Google Scholar 

  • Hunt T (1848) On Dr. Castle's case of supposed poisoning by Fowler's solution. Prov Med Surg J 12:391

    Google Scholar 

  • Bouteille B, Oukem O, Bisser S et al (2003) Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 17:171–181

    Article  CAS  Google Scholar 

  • Steverding D (2008) The history of African trypanosomiasis. Parasit Vectors 1:3

    Article  Google Scholar 

  • Livingstone D (1858) Arsenic as a remedy for the tse tse bite. Br Med J 1:360–361

    Article  Google Scholar 

  • Manchester K (2001) Antoine Béchamp: père de la biologie. Oui ou non? Endeavour 25:68–73

    Article  CAS  Google Scholar 

  • Béchamp A (1863) De l'action de la chaleur sur l'arséniate d'aniline et de la formation d'un anilide de l'acide arsénique. Compt Rend 56:1172–1175

    Google Scholar 

  • Thomas H (1905) Some experiments in the treatment of trypanosmiasis. Br Med J 1:1140–1143

    Article  CAS  Google Scholar 

  • Scherber G (1907) The atoxyl treatment of syphilis. Wien Klin Wochenschr 20:1165–1172

    CAS  Google Scholar 

  • Blumenthal F (1902) Über Metaarsensäureanilid (atoxyl). Med Woche 3:163

    Google Scholar 

  • Ehrlich P, Bertheim A (1907) Über p-Aminophenylarsinsäure. Ber Dtsch Chem Ges 40:3292–3297

    Article  CAS  Google Scholar 

  • Anonymous (1910) Action of Atoxyl on Eyes. Cal State J Med 8:384

    Google Scholar 

  • Knopf H, Fabian R (1909) Further results of Atoxyl treatment. Berl Klin Wochenschr 46:99–101

    CAS  Google Scholar 

  • Jacobs WA, Heidelberger M (1919) Aromatic arsenic compounds. II. The amides and alkylamides of N-arylglycine arsonic acids. J Am Chem Soc 41:1809–1821

    Article  CAS  Google Scholar 

  • Pearce L (1925) Tryparsamide treatment of African sleeping sickness. Science 61:90–92

    Article  CAS  Google Scholar 

  • Pearce L (1921) Treatment of human trypanosomiasis with tryparsamide (sodium salt of N-phenylglycineamide-p-arsonic acid). J Exp Med 34(1):1–104

    Article  CAS  Google Scholar 

  • Hawking F (1941) Drug resistance acquired during the treatment of sleeping sickness with tryparsamide and with Bayer 205. Am J Trop Med 21:469–475

    CAS  Google Scholar 

  • Friedheim EAH (1944) Trypanocidal and spirochetocidal arsenicals derived from s-triazine. J Am Chem Soc 66:1775–1778

    Article  CAS  Google Scholar 

  • Friedheim EAH (1942) Substituted [1,3,5-triazinyl-(6)]-aminophenyl-arsonic acids and process for manufacture of same. US Patent 2,295,574

    Google Scholar 

  • Doak G, Steinman H, Eagle H (1944) Arsenoso compounds containing amide groups. J Am Chem Soc 66:194–197

    Article  CAS  Google Scholar 

  • Banks C, Gruhzit O, Tillitson E et al (1944) Arylaminoheterocycles. III. Arsenicals of anilinotriazines. J Am Chem Soc 66:1771–1775

    Article  CAS  Google Scholar 

  • Jonchère H, Gomer J, Reynaud R (1953) Contribution à l'étude de produits à radical mélaminyl dans le traitement de la trypanosomiase humaine. Bull Soc Pathol Exot 46:386–396

    Google Scholar 

  • Friedheim EAH (1948) Melarsen oxide in the treatment of human African trypanosomiasis. Ann Trop Med 42:357–363

    CAS  Google Scholar 

  • Peters R, Stocken L, Thompson R (1945) British Anti-Lewisite (BAL). Nature 156:616–619

    Article  CAS  Google Scholar 

  • Friedheim EAH (1953) Heterocyclic metal and sulfur organic compounds. US Patent 2,664,432

    Google Scholar 

  • Gibaud S, Alfonsi R, Mutzenhardt P et al (2006) (2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. J Organomet Chem 691:1081–1084

    Article  CAS  Google Scholar 

  • Friedheim EAH (1952) Propylene glycol solution of arsenic medicaments. US Patent 3,593,434

    Google Scholar 

  • Watson HJC (1962) Mel W: A field trial in the treatment of Trypanosoma gambiense sleeping sickness. Trans R Soc Trop Med Hyg 56:231–235

    Article  CAS  Google Scholar 

  • Watson HJC (1965) Mel W: final report on a field trial in the treatment of Trypanosoma gambiense sleeping sickness. Trans R Soc Trop Med Hyg 59:163–170

    Article  CAS  Google Scholar 

  • Loiseau PM, Lubert P, Wolf JG (2000) Contribution of dithiol ligands to In vitro and In vivo trypanocidal activities of dithiaarsanes and investigation of ligand exchange in an aqueous solution. Antimicrob Agents Chemother 44:2954–2961

    Article  CAS  Google Scholar 

  • Pépin J, Milord F, Khonde A et al (1994) Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans R Soc Trop Med Hyg 88:447–452

    Article  Google Scholar 

  • Pépin J, Milord F (1991) African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. Trans R Soc Trop Med Hyg 85:222–224

    Article  Google Scholar 

  • Kennedy PGE (2006) Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Int J Parasitol 36:505–512

    Article  CAS  Google Scholar 

  • Adams JH, Haller L, Boa FY et al (1986) Human African trypanosomiasis (T.b. gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 12:81–94

    Article  CAS  Google Scholar 

  • Friedheim EAH (1951) Mel B in the treatment of tryparsamide resistant T. gambiense sleeping sickness: observations on drug resistance in the trypanosomes of the French Cameroon. Am J Trop Med Hyg 31:218–226

    CAS  Google Scholar 

  • Friedheim EAH (1949) Mel B in the treatment of human trypasonomiasis. Am J Trop Med Hyg 29:173–180

    CAS  Google Scholar 

  • Burri C, Nkunku S, Merolle A et al (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355:1419–1425

    Article  CAS  Google Scholar 

  • Pépin J, Mpia B (2006) Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Trans R Soc Trop Med Hyg 100:437–441

    Article  Google Scholar 

  • Pépin J, Milord F, Guern C et al (1989) Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1:1246–1250

    Article  Google Scholar 

  • Carter NS, Fairlamb AH (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361:173–176

    Article  CAS  Google Scholar 

  • Balasegaram M, Young H, Chappuis F et al (2009) Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Trans R Soc Trop Med Hyg 103:280–290

    Article  CAS  Google Scholar 

  • Jennings FW (1993) Combination chemotherapy of CNS trypanosomiasis. Acta Trop 54:205–213

    Article  CAS  Google Scholar 

  • Pépin J, Ethier L, Kazadi C et al (1992) The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J Trop Med Hyg 47:133–140

    Google Scholar 

  • Kennedy PGE (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64:116–126

    Article  Google Scholar 

  • Harper K, Ocampo P, Steiner B et al (2008) On the origin of the treponematoses: a phylogenetic approach. PLoS Negl Trop Dis 2:e148

    Article  Google Scholar 

  • Ehrlich P, Bertheim A (1911) Derivatives of oxyarylarsinic acids and process of making same. US Patent 986,148

    Google Scholar 

  • Christiansen WG (1920) Hypophosporous acid preparation of arsphenamine. (3, 3-diamino-4, 4-dihydroxy-arseno-benzene dihydrochloride. J Am Chem Soc 42:2402–2405

    Article  CAS  Google Scholar 

  • Lloyd NC, Morgan HW, Nicholson BK et al (2005) The composition of Ehrlich's Salvarsan: resolution of a century-old debate. Angew Chem Int Ed 44:941–944

    Article  CAS  Google Scholar 

  • Pariser RJ (2008) Syphilis rules. Clin Dermatol 26:399–410

    Article  Google Scholar 

  • Anonymous (1911) Salvarsan, new indications. Cal State J Med 9:265–266

    Google Scholar 

  • Kaufmann SHE (2008) Paul Ehrlich: founder of chemotherapy. Nat Rev Drug Discov 7:373

    Article  CAS  Google Scholar 

  • Kolmer J, Schamberg J (1912) Experimental studies on the administration of salvarsan by mouth to animals and man. J Exp Med 15:498–509

    Article  CAS  Google Scholar 

  • Fleming A, Florey HW, Bodenham DC et al (1944) Discussion on penicillin. Proc R Soc Med 37:101–112

    CAS  Google Scholar 

  • Chain E, Florey HW (1944) Penicillin. Endeavour 3:3–14

    CAS  Google Scholar 

  • Chain E, Florey HW, Gardner AD et al (1940) Penicillin as a chemotherapeutic agent. Lancet 2:226–228

    Article  Google Scholar 

  • Florey HW, Chain E (1945) Penicillin: demonstration of its value as a chemotherapeutic agent. Preliminary report of a new method. Med Rec (1866-1922) 158:217–219

    CAS  Google Scholar 

  • Florey HW (1944) Penicillin: a survey. Br Med J 2:169–170

    Article  CAS  Google Scholar 

  • Heatley NG (1945) Administration of penicillin by mouth. Lancet 1:590–591

    Article  Google Scholar 

  • Ehrlich P, Karrer P, Georg Speyer H (1915) Arseno-metallic compounds. Ber Dtsch Chem Ges 48:1634–1644

    Article  CAS  Google Scholar 

  • Raiziss GW, Kremens A (1926) Arseno-bismuth compound and process of making same. US Patent 1,605,691

    Google Scholar 

  • Stokes JH, Chambers SO (1927) Bismuth arsphenamine sulphonate. J Am Med Assoc 89:1500

    Article  Google Scholar 

  • Rayburn CR, Boyd TM (1931) The treatment of neurosyphilis - Observations on 393 patients over a period of five years. Am J Syph 15:168–184

    Google Scholar 

  • World Health Organisation (1997) Weekly epidemiological record 72:97–100

    Google Scholar 

  • Gunn H (1918) Amebiasis: its radical cure with combined emetin and salvarsan products. Cal State J Med 16:240–244

    CAS  Google Scholar 

  • Fourneau E (1925) Relation between chemical constitution and therapeutic action. In: Union Internationale de chimie pure et appliquée (ed.) Comptes rendus de la sixième conférence internationale de la chimie, Bucarest

    Google Scholar 

  • James DM (1949) The relation between the effect of certain therapeutic agents on infusoria and on pathogenic protozoa. Ann Trop Med Parasitol 43:164–173

    CAS  Google Scholar 

  • David NA, Anderson HH, Koch DA et al (1932) Comparative toxicity and protozoacidal action of acetarsone, carbarsone and certain related quinquevalent arsenical compounds. Proc Soc Exp Biol Med 29:125–128

    CAS  Google Scholar 

  • Chopra RN, Sen B, Sen G (1935) Amibiarson in the treatment of chronic intestinal amebiasis. Ind Med Gaz 70:324–328

    CAS  Google Scholar 

  • Anonymous. (1971) Food additives. Carbarsone (not USP) in combination with bacitracin methylene disalicylate. Fed Regist 36:24001–24002

    Google Scholar 

  • Schneider J, Dupoux R, Montezin G (1957) Traitement de l'amibiase intestinale par le diphetarsone-spiramycine (6 753 RP). Bull Soc Pathol Exot Filiales 50:600–606

    CAS  Google Scholar 

  • Elsdondew R, Powell SP, Wilmot AJ (1957) Diphetarsone in the treatment of acute amoebic dysentery. J Trop Med Hyg 60:16–18

    CAS  Google Scholar 

  • Schneider J, Biguet J, Machez J (1960) Treatment of oxyuriasis by diphetarsone-spiramycin and by diphetarsone. Therapie 15:648–654

    CAS  Google Scholar 

  • Friedheim EAH (1949) A five day peroral treatment of yaws with stb, a new trivalent arsenical. Am J Trop Med Hyg 29(suppl 1):185

    CAS  Google Scholar 

  • Anonyme (1953) New and nonofficial remedies; arsthinol. J Am Med Assoc 152:531

    Google Scholar 

  • Abernathy CO, Liu YP, Longfellow D et al (1999) Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect 107:593–597

    Article  CAS  Google Scholar 

  • Stohrer G (1991) Arsenic: opportunity for risk assessment. Arch Toxicol 65:525–531

    Article  CAS  Google Scholar 

  • Cutler E, Bradford E (1878) Action of iron, cod liver oil and arsenic on globular richness of the blood. Am J Med Sci 75:74–84

    Article  Google Scholar 

  • Stockman R (1898) The action of arsenic on the bone-marrow and blood. J Physiol 23:376–382

    CAS  Google Scholar 

  • Forkner C, Scott T (1931) Arsenic as a therapeutic agent in chronic myelogenous leukemia. J Am Med Assoc 97:3–5

    Article  Google Scholar 

  • Rontgen W (1896) On a new kind of rays. Science 3:227–231

    Article  CAS  Google Scholar 

  • Senn N (1903) Case of spleno-medullary leukemia successfully treated by the use of roentgen ray. Med Rec NY 63:281

    Google Scholar 

  • Wang ZY (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48(suppl 1):S72–S76

    Article  CAS  Google Scholar 

  • Sun HD, Li H, Ma L et al (1992) Treatment of acute promyelocytic leukemia by Ailing-1 therapy (in Chinese). Chin J Integr Trad Med West Med 12:170–172

    Google Scholar 

  • Zhang P, Wang SY, Lu LH et al (1996) Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia (in Chinese). Clin J Hematol 17:58–62

    Google Scholar 

  • Lu DP, Qiu JY, Jiang B et al (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99:3136–3143

    Article  CAS  Google Scholar 

  • Soignet SL, Tong WP, Hirschfeld S et al (1999) Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 44:417–421

    Article  CAS  Google Scholar 

  • Soignet SL, Maslak P, Wang ZG et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341–1348

    Article  CAS  Google Scholar 

  • Warrell R, Soignet S, Maslak P et al (1998) Initial western study of arsenic trioxide (As2O3) in acute promyelocytic leukemia (APL). Proc Am Soc Clin Oncol 17:6a

    Google Scholar 

  • Chen GQ, Zhu J, Shi XG et al (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML- RARα/PML proteins. Blood 88:1052–1061

    CAS  Google Scholar 

  • Dai J, Weinberg RS, Waxman S et al (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268–277

    CAS  Google Scholar 

  • Jing Y, Dai J, Chalmers-Redman RME et al (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102–2111

    CAS  Google Scholar 

  • Schmidt A, Koppelt J, Neustadt M et al (2007) Mass spectrometric evidence for different complexes of peptides and proteins with arsenic (III), arsenic (V), copper (II), and zinc (II) species. Rapid Commun Mass Spectrom 21:153–163

    Article  CAS  Google Scholar 

  • Rousselot P, Labaume S, Marolleau JP et al (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59:1041–1048

    CAS  Google Scholar 

  • Wang ZG, Rivi R, Delva L et al (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92:1497–1504

    CAS  Google Scholar 

  • Konig A, Wrazel L, Warrell RP et al (1997) Comparative activity of melarsoprol and arsenic trioxide in chronic B- cell leukemia lines. Blood 90:562–570

    CAS  Google Scholar 

  • De Los SJ, Thomas G (2007) Anemia correction in malignancy management: threat or opportunity? Gynecol Oncol 105:517–529

    Article  Google Scholar